India, Aug. 17 -- Evaxion A/S (EVAX), a clinical-stage TechBio company developing vaccines using its AI-Immunology platform, announced the expansion and refocusing of its R&D pipeline with the addition of EVX-05, an off-the-shelf therapeutic vaccine candidate for glioblastoma.
EVX-05 Program
EVX-05 is designed to target novel, conserved antigens derived from endogenous retroviruses (ERVs) that are shared among glioblastoma patients. The targets were identified using Evaxion's AI-Immunology platform, supporting the development of an off-the-shelf cancer vaccine approach.
Evaxion is collaborating with experts from Duke University School of Medicine to advance EVX-05. The academic team is expected to conduct initial clinical testing of the ...